Percutaneous left atrial appendage closure procedural techniques and outcomes

JACC: Cardiovascular Interventions

Volumn 7, Issue 11, 2014, Pages 1205-1220

  Saw, Jacqueline ^a   Lempereur, Mathieu ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amplatzer Cardiac Plug; Amulet; Lariat; Left atrial appendage closure; WATCHMAN

Indexed keywords

WARFARIN;

AMPLATZER VASCULAR PLUG; ANTICOAGULATION; BLEEDING; CEREBROVASCULAR ACCIDENT; DEVICE COMPARISON; DEVICE SAFETY; ENDOLEAK; GUIDE WIRE; HEART ATRIUM FIBRILLATION; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MEDICAL DEVICE COMPLICATION; OCCLUSION BALLOON CATHETER; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUTURE; SUTURE DELIVERY DEVICE; THROMBUS; TREATMENT OUTCOME; ADVERSE EFFECTS; ATRIAL FIBRILLATION; COMPLICATION; DEVICES; EQUIPMENT DESIGN; HEART ATRIUM APPENDAGE; HEART CATHETERIZATION; HEMORRHAGE; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME;

ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC CATHETERIZATION; EQUIPMENT DESIGN; HEMORRHAGE; HUMANS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922573916     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.05.026     Document Type: Review

References (47)

1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142-7.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147: 1561-4.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
4. Wolf PA, D?Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22: 312-8.
5. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001;32:392-8.
6. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-36.
7. Camm AJ, Lip GY, De Caterina R, et al., for the ESC Committee for Practice Guidelines. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation. Eur Heart J 2012;33: 2719-47.
8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
9. Ezekowitz MD, Bridgers SL, James KE, et al., for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
10. Nieuwlaat R, Capucci A, Camm AJ, et al., for the European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34.
11. Granger CB, Alexander JH, McMurray JJ, et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
12. Patel MR, Mahaffey KW, Garg J, et al., for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
14. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165: 1095-106.
15. Gersh BJ, Freedman JE, Granger CB. [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments]. Rev Esp Cardiol 2011;64: 260-8.
16. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 2011;105:574-8.
17. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61: 755-9.
18. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 2008;52:924-9.
19. García-Fernández MA, Pérez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003;42:1253-8.
20. Tzikas A. LAAO for stroke prevention in AF: multicenter experience with the Amplatzer Cardiac Plug. Paper presented at: Transcatheter Cardiovascular Therapeutics 2013; October 28 to November 1, 2013; San Francisco, CA.
21. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105:1887-9.
22. Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. J Am Coll Cardiol Intv 2009;2: 594-600.
23. Meier B, Palacios I, Windecker S, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003;60:417-22.
24. Nietlispach F, Gloekler S, Krause R, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv 2013;82:283-9.
25. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2013;62:108-18.
26. Romero J, Husain SA, Kelesidis I, Sanz J, Medina HM, Garcia MJ. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a metaanalysis. Circ Cardiovasc Imaging 2013;6:185-94.
27. Saw J, DeJong P, Lempereur M, et al. CT angiography is a useful non-invasive surveillance imaging test after percutaneous left atrial appendage closure (abstr). J Am Coll Cardiol 2014;64, Suppl:B51.
28. Koermendy D, Nietlispach F, Shakir S, et al. Amplatzer left atrial appendage occlusion through a patent foramen ovale. Catheter Cardiovasc Interv 2014 Jan 8 [E-pub ahead of print].
29. Holmes DR, Reddy VY, Turi ZG, et al., for the PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42.
30. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011; 123:417-24.
31. Reddy VY, Doshi SK, Sievert H, et al., for the PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720-9.
32. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1-12.
33. Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551-6.
34. Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer Cardiac Plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011;77:700-6.
35. Lam YY, Yip GW, Yu CM, et al. Left atrial appendage closure with Amplatzer Cardiac Plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. Catheter Cardiovasc Interv 2012;79:794-800.
36. Damonte A, Costantini C, Pedra C, et al. Percutaneous closure of the left atrial appendage: initial experience in Latin America (abstr). J Am Coll Cardiol 2013;62:B211.
37. López-Mínguez JR, Eldoayen-Gragera J, González-Fernández R, et al. Immediate and one-year results in 35 consecutive patients after closure of left atrial appendage with the Amplatzer Cardiac Plug. Rev Esp Cardiol (Engl Ed) 2013;66:90-7.
38. Streb W, Szymala M, Kukulski T, et al. Percutaneous closure of the left atrial appendage using the Amplatzer Cardiac Plug in patients with atrial fibrillation: evaluation of safety and feasibility. Kardiol Pol 2013;71:8-16.
39. Urena M, Rodes-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 2013;62:96-102.
40. Meerkin D, Butnaru A, Dratva D, Bertrand OF, Tzivoni D. Early safety of the Amplatzer Cardiac Plug for left atrial appendage occlusion. Int J Cardiol 2013;168:3920-5.
41. Park JW, Sievert H, Schillinger W, et al. Results of the Amplatzer Cardiac Plug European multicenter prospective observational study (abstr). J Am Coll Cardiol 2012;60, Suppl:B27.
42. Bethencourt A, Lopez-Minguez JR, Valdes M, et al. Prevención embólica de pacientes en fibrilación auricular: ¿es segura la oclusión percutánea de la orejuela auricular izquierda con el dispositivo ACP Amplatzer? (abstr). Rev Esp Cardiol 2010;63:29.
43. Kefer J, Vermeersch P, Budts W, et al. Transcatheter left atrial appendage closure for stroke prevention in atrial fibrillation with Amplatzer Cardiac Plug: the Belgian Registry. Acta Cardiol 2013;68:551-8.
44. Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation. Results from the US Transcatheter LAA Ligation Consortium. J Am Coll Cardiol 2014;64:565-72.
45. Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012;59: 923-9.
46. Wunderlich N, Wilson N, Sievert H. A novel approach to treat residual peridevice leakage after left-atrial appendage closure. Catheter Cardiovasc Interv 2013;82:313-9.
47. Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol 2012; 60:531-8.